Company: TBPH
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001104659-25-033819
Chunk: 66

Company: Theravance Biopharma, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 66
---
ham, our Chief Executive Officer. The dollar amounts reported in this column are the amounts of total compensation reported for Mr. Winningham in the “Total” column of the Summary Compensation Table in the applicable fiscal year.

​

(2)

In accordance with SEC rules, the following adjustments were made to determine the compensation actually paid to our PEO during fiscal years 2024, 2023 and 2022, which consisted solely of adjustments to the PEO’s equity awards:

​

| Description of Adjustment                                                                                                                                                                    | ​ | ​ | 2024 |   |            |   | ​ | ​ | 2023 |   |            |   | ​ | ​ | 2022 |   |            |   | ​ |
|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:--|:--|:-----|:--|-----------:|:--|:--|:--|:-----|:--|-----------:|:--|:--|:--|:-----|:--|-----------:|:--|:--|
| Summary Compensation Table – Total Compensation                                                                                                                                              | ​ | ​ | ​    | $ |  3,995,931 | ​ | ​ | ​ | ​    | $ |  4,318,531 | ​ | ​ | ​ | ​    | $ |  6,272,907 | ​ | ​ |
| - grant date fair value of option awards and stock awards granted in the covered fiscal year                                                                                                 | ​ | ​ | ​    | $ | -2,443,500 | ​ | ​ | ​ | ​    | $ | -3,015,100 | ​ | ​ | ​ | ​    | $ | -4,497,647 | ​ | ​ |
| + fair value at fiscal year end of outstanding and unvested option awards and stock awards granted in the covered fiscal year                                                                | ​ | ​ | ​    | $ |  2,405,375 | ​ | ​ | ​ | ​    | $ |  3,327,588 | ​ | ​ | ​ | ​    | $ |  5,173,856 | ​ | ​ |
| + change in fair value of outstanding and unvested option awards and stock awards granted in prior fiscal years                                                                              | ​ | ​ | ​    | $ | -1,354,021 | ​ | ​ | ​ | ​    | $ |   -120,820 | ​ | ​ | ​ | ​